PT-141 for perimenopause: what the evidence actually shows

What's this video probably claiming?

Based on the caption and hashtags, @bnuttbutter is documenting a personal experience with PT-141 (bremelanotide), a melanocortin receptor agonist, and framing it as relevant to perimenopause. The side effect she's joking about, flushing and the urge to cool down, is one of the most commonly reported short-term effects of this compound. The implicit claim here is that PT-141 offers something useful for perimenopausal women, likely around sexual desire or libido, which tends to drop significantly during the hormonal transition years. She's probably positioning this as a self-experimentation journey with a peptide that her audience already knows something about. The perimenopause angle is significant because it situates PT-141 not just as a general sexual wellness compound but as a targeted solution for a specific hormonal phase, and that framing deserves some scrutiny before it spreads to 178,000 more viewers.

What does the science actually show?

PT-141 has one legitimate FDA approval: Vyleesi, approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. That's not a minor asterisk. The important trial published by Kingsberg et al. (2019, Journal of Sexual Medicine) showed bremelanotide 1.75mg subcutaneous injection increased satisfying sexual events by roughly 0.5 events per month compared to placebo, with about 25% of women reporting meaningful improvement on the Female Sexual Distress Scale. Those are real but modest numbers. Nausea occurred in 40% of participants and flushing in 20%, which is exactly what this creator is experiencing. Critically, the trial excluded postmenopausal and perimenopausal women. There is no strong randomized controlled trial establishing efficacy specifically in perimenopause, where the hormonal environment, including declining estrogen and progesterone, is meaningfully different from the premenopausal state studied in registration trials.

Where does the social media noise diverge from clinical reality?

The TikTok peptide community has collectively decided PT-141 is a broadly applicable libido fix for any woman experiencing sexual changes, and perimenopause content is accelerating that narrative. The problem is threefold. First, compounded PT-141 is not equivalent to FDA-approved Vyleesi. Formulation, concentration, and purity vary across compounding pharmacies, and there is no head-to-head data. Second, the side effect profile being played for laughs here, flushing and facial heat, is actually the compound's mechanism working through melanocortin receptors, and in some users it also produces nausea, blood pressure elevation, and hyperpigmentation with repeated use. Gottesdiener et al. (2019, Clinical Pharmacology) documented transient blood pressure increases averaging 6 mmHg systolic. Third, perimenopause-associated low libido often has overlapping contributors, including sleep disruption, estrogen decline, and relationship factors, that PT-141 does not address. Treating one variable while ignoring others is not a protocol, it's a shortcut.

What should you actually know?

If you're perimenopausal and experiencing low sexual desire, PT-141 might be one piece of a conversation with a clinician, not a starting point you launch on your own after watching TikTok. The FDA-approved version, Vyleesi, exists and was studied at a specific dose in a specific population that does not include you if you're perimenopausal. Compounded versions circulating in peptide communities carry additional unknowns. The side effects this creator is describing are real, expected, and not always benign. A 2023 review by Pyke (Journal of Sexual Medicine) noted that optimal candidate selection for bremelanotide remains poorly defined and that clinician guidance is essential given cardiovascular contraindications. Perimenopausal hormone therapy, addressing estrogen and testosterone levels directly, has a far stronger evidence base for sexual function in this life stage than any melanocortin agonist does. That doesn't make PT-141 useless, but it makes unsupervised self-experimentation a genuinely risky way to find out.